Bristol-Myers Squibb has recently seen considerable activity and some promising developments. The pharmaceutical giant has been selected by Veeva Systems as a Vault CRM client, reassuring the market. It has commenced direct sales of its psoriasis medication, Sotyktu, to cash-paying US consumers and is reporting compelling data on multiple myeloma. Also of note is the FDA's decision to fast-track BMS's Alzheimer's drug, with analyst suggest this may boost stock value. In a later development, BMS received approval on another front, with its anti-MTBR-Tau-targeting antibody BMS-986446 being granted fast track by the FDA for Alzheimer's treatment. A partnership with Takeda and Astex Pharmaceuticals has been established to share structural biology data for an AI-driven drug discovery model, termed OpenFold3, marking a collaborative approach to boost R&D efficiency. The company is also considering partially selling and leasing back its substantial Summit campus. However, there is some friction with a lawsuit over a $2B Athene annuity deal being allowed to proceed. BMS has delivered strong yields and it remains of interest to investors despite some market inconsistency.
Bristol-Myers Squibb News Analytics from Mon, 03 Feb 2025 08:00:00 GMT to Sat, 04 Oct 2025 14:15:42 GMT -
Rating 6
- Innovation -2
- Information 7
- Rumor -5
